Race Oncology Submits Patent Applications for (E,E)-bisantrene, Enabling New Formulation and Increased Clinical and Commercial Potential

Race Oncology has submitted three new patent applications for its cancer drug, (E,E)-bisantrene, following a breakthrough in its chemistry. The original formulation was a mixture of three isomers that could convert between each other when exposed to light, leading to inconsistent patient outcomes. The company has isolated the active isomer, enabling "composition of matter" IP protection and increasing its clinical and commercial potential. This repositioning allows Race to resume using the original drug formulation, which is already eligible for a phase three trial in AML. Accelerated patent examination is underway, potentially supporting commercial negotiations.

Race Oncology, a biopharmaceutical company, has submitted three new patent applications for its cancer drug, (E,E)-bisantrene, following a breakthrough in its chemistry. The original formulation was a mixture of three isomers that could convert between each other when exposed to light, leading to inconsistent patient outcomes. The company has isolated the active isomer, enabling "composition of matter" IP protection and increasing its clinical and commercial potential. This repositioning allows Race to resume using the original drug formulation, which is already eligible for a phase three trial in AML. Accelerated patent examination is underway, potentially supporting commercial negotiations.

The breakthrough in isolating the active isomer addresses a significant challenge in the drug's development. The mixture of isomers led to inconsistent patient outcomes due to the varying potency of each isomer. By isolating the active isomer, Race Oncology can ensure consistent efficacy and safety, which is crucial for clinical trials and commercialization.

The new patents, which cover the isolated active isomer and its use in cancer treatment, provide Race Oncology with a strong intellectual property position. This IP protection can help the company secure favorable licensing agreements and negotiate better terms with potential partners or acquirers.

The phase three trial for (E,E)-bisantrene in AML is expected to commence soon, following the successful completion of phase one and two trials. The company's ability to resume using the original drug formulation, now with a more consistent and effective active ingredient, could accelerate the drug's development and approval process.

Race Oncology's success in isolating the active isomer and securing new patents is a significant milestone in its efforts to bring innovative cancer therapies to market. The company's focus on improving the consistency and efficacy of its drug candidates positions it well to compete in the crowded cancer drug market.